![XBiotech Inc](/common/images/company/N_XBIT.png)
XBiotech Inc is a United States based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for... XBiotech Inc is a United States based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States. Show more
AUSTIN, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for...
AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it’s campus headquarters with the construction of a new, state-of-the-art research and...
AUSTIN, Texas, Nov. 14, 2023 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) today announced that Alan Kivitz M.D. is now Lead Investigator & Study Chairman for its clinical research program for...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.57 | 8.5843373494 | 6.64 | 7.25 | 5.88 | 84608 | 6.36155106 | CS |
4 | 2.16 | 42.7722772277 | 5.05 | 7.25 | 4.845 | 102036 | 6.11122298 | CS |
12 | -0.88 | -10.8776266996 | 8.09 | 9.45 | 4.24 | 99748 | 6.33635301 | CS |
26 | 3.01 | 71.6666666667 | 4.2 | 9.96 | 4.145 | 85626 | 6.89935398 | CS |
52 | 1.97 | 37.5954198473 | 5.24 | 9.96 | 3.51 | 51872 | 6.44033645 | CS |
156 | -8.79 | -54.9375 | 16 | 16.63 | 3 | 61694 | 7.2166622 | CS |
260 | -0.14 | -1.90476190476 | 7.35 | 33.2 | 3 | 135186 | 14.40707874 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.